ArticleJournal for immunotherapy of cancer2021

Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report.

Carolin Blumendeller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.